CSL Behring
CSL Behring sponsors 71 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 49 completed. 35 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hemophilia B, with 3 trials.
Trial Pipeline
71 total, page 2 of 2
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
NCT01486927
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT01496274
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
NCT01490450
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
NCT01403064
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
NCT01373151
Retrospective Chart Review of Subcutaneous IgG Use in Infants
NCT01166074
Patient Registry Study of Berinert® in Normal Clinical Practice
NCT01108848
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00945906
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00885742
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
NCT00883090
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
NCT00803101
Rabies Immune Plasma Booster Study
NCT01063140
Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
NCT00708435
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
NCT00719680
Human Fibrinogen - Pharmacokinetics
NCT00496262
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
NCT00419341
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
NCT00261833
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT00322556
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
NCT00292981
Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
NCT00168103
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
NCT00168090
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 22 |
| Phase 3 | 29 |
| Phase 4 | 6 |
Therapeutic Areas
What the Pipeline for CSL Behring Shows
According to the ClinicalTrials.gov registry, CSL Behring is linked to 71 US clinical trials across every stage of research activity. Of those, 12 studies are currently recruiting, about 17% of the sponsor's indexed portfolio, and 49 are already marked complete, representing roughly 69% of the total.
The phase mix for CSL Behring reports 35 late-stage studies (Phase 3 and Phase 4 combined) and 28 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for CSL Behring is Hemophilia B with 3 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.